2021
Provider‐ and patient‐level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma
Spees LP, Wheeler SB, Jackson BE, Baggett CD, Wilson LE, Greiner MA, Kaye DR, Zhang T, George D, Scales CD, Pritchard JE, Leapman M, Gross CP, Dinan MA. Provider‐ and patient‐level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma. Cancer Medicine 2021, 10: 6653-6665. PMID: 34480518, PMCID: PMC8495289, DOI: 10.1002/cam4.4201.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaPatient-level factorsRenal cell carcinomaCell carcinomaRisk ratioState cancer registry dataPatient-level predictorsPatient-level characteristicsCancer registry dataProvider Enumeration SystemMRCC diagnosisMedical oncologyInsurance typeMedicare patientsRegistry dataFemale providersPatientsMedian proportionPoisson regressionCare issuesPrivate insuranceMale providersAdherenceCarcinomaAnticancer agentsPatterns and predictors of oral anticancer agent utilization in diverse metastatic renal cell carcinoma patients.
Wheeler S, Spees L, Jackson B, Baggett C, Wilson L, Greiner M, George D, Scales C, Pritchard J, Dinan M. Patterns and predictors of oral anticancer agent utilization in diverse metastatic renal cell carcinoma patients. Journal Of Clinical Oncology 2021, 39: 279-279. DOI: 10.1200/jco.2021.39.6_suppl.279.Peer-Reviewed Original ResearchMetastatic renal cell carcinoma patientsRenal cell carcinoma patientsCell carcinoma patientsOral anti-cancer agentsCarcinoma patientsRisk ratioPatterns of useRisk differenceGreater comorbidity burdenMetastatic RCC patientsPopulation-based studyPatient-level characteristicsMonths of preAdjusted risk differencePoor quality careComorbidity burdenIndex dateAnti-cancer agentsMetastatic RCCPatient characteristicsContinuous enrollmentRCC patientsTreatment advancesType of insurancePatients
2020
Disparities in utilization of oral anticancer agents and related costs in elderly patients with metastatic renal cell carcinoma in the United States.
Wilson L, Spees L, Pritchard J, Greiner M, Scales C, Baggett C, Kaye D, George D, Zhang T, Wheeler S, Dinan M. Disparities in utilization of oral anticancer agents and related costs in elderly patients with metastatic renal cell carcinoma in the United States. Journal Of Clinical Oncology 2020, 38: 106-106. DOI: 10.1200/jco.2020.38.29_suppl.106.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaOral anticancer agentsRenal cell carcinomaPatient characteristicsCell carcinomaManagement of mRCCSEER-Medicare patientsMultivariable-adjusted modelsMajority of patientsPatient-level characteristicsAnticancer agentsMedicare Part D benefitPart D benefitSurvival persistCertain comorbiditiesElderly patientsMultivariable adjustmentMarried patientsMetastatic diagnosisRace/ethnicity categoriesAdvanced ageInclusion criteriaHispanic ethnicityPatientsPocket spending